Existing STING antagonists (H-151, SN-011, Compound 18) developed for autoinflammatory diseases can be repurposed to block both neuronal and glial cGAS/STING activation downstream of TDP-43-mediated mtDNA release. STING represents the most druggable node in the pathway with well-characterized binding pockets, established structure-activity relationships, and existing tool compounds with moderate-to-excellent CNS penetration. The translational path is accelerated by existing safety data from auto
During early/prodromal ALS, cGAS/STING activation may be moderate and potentially adaptive (mitophagy induction), while during symptomatic phase it becomes hyperactivated and drives neurodegeneration. Therapeutic timing determines whether STING inhibition is protective or detrimental. This hypothesis introduces a critical clinical development consideration: identifying the therapeutic window for intervention.
Verdict Summary
8/10
dimensions won
STING Antagonists as ALS Therapeutics: D
2/10
dimensions won
Temporal cGAS-STING Activation Stage-Spe
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
0.50
Evidence
0.68
0.48
Novelty
0.55
0.70
Feasibility
0.82
0.55
Impact
0.78
0.68
Druggability
0.85
0.75
Safety
0.58
0.60
Competition
0.70
0.62
Data
0.72
0.45
Reproducible
0.75
0.52
Score Breakdown
Dimension
STING Antagonists as ALS Thera
Temporal cGAS-STING Activation
Mechanistic
0.720
0.500
Evidence
0.680
0.480
Novelty
0.550
0.700
Feasibility
0.820
0.550
Impact
0.780
0.680
Druggability
0.850
0.750
Safety
0.580
0.600
Competition
0.700
0.620
Data
0.720
0.450
Reproducible
0.750
0.520
Evidence
STING Antagonists as ALS Therapeutics: Drug Repurposing
No evidence citations yet
Temporal cGAS-STING Activation Stage-Specific Therapeutic Ta
No evidence citations yet
Debate Excerpts
STING Antagonists as ALS Therapeutics: Drug Repurp
4 rounds · quality: 0.73
Theorist
# Therapeutic Hypotheses: TDP-43/cGAS/STING in Neurodegeneration
## Hypothesis 1: Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I Interferon Signaling...
Skeptic
# Critical Evaluation of TDP-43/cGAS/STING Hypotheses in Neurodegeneration
---
## Hypothesis 1: Chronic cGAS/STING Hyperactivation via Sustained Type I IFN Signaling
### Weak Links
- **Unproven chr...
Domain Expert
# Feasibility Assessment: TDP-43/cGAS/STING Therapeutic Hypotheses in Neurodegeneration
## Executive Summary
The source paper (Yu et al., Cell 2020) establishes a credible mechanistic link between T...
Synthesizer
{
"ranked_hypotheses": [
{
"title": "STING Antagonists as ALS Therapeutics: Drug Repurposing",
"description": "Existing STING antagonists (H-151, SN-011, Compound 18) developed for a...
# Therapeutic Hypotheses: TDP-43/cGAS/STING in Neurodegeneration
## Hypothesis 1: Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I Interferon Signaling...
Skeptic
# Critical Evaluation of TDP-43/cGAS/STING Hypotheses in Neurodegeneration
---
## Hypothesis 1: Chronic cGAS/STING Hyperactivation via Sustained Type I IFN Signaling
### Weak Links
- **Unproven chr...
Domain Expert
# Feasibility Assessment: TDP-43/cGAS/STING Therapeutic Hypotheses in Neurodegeneration
## Executive Summary
The source paper (Yu et al., Cell 2020) establishes a credible mechanistic link between T...
Synthesizer
{
"ranked_hypotheses": [
{
"title": "STING Antagonists as ALS Therapeutics: Drug Repurposing",
"description": "Existing STING antagonists (H-151, SN-011, Compound 18) developed for a...